Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Ventrus Biosciences has been awarded notice of allowance (NoA) from the US Patent and Trademark Office (USPTO) for patent application no. 09/355,928.
Subscribe to our email newsletter
The patent entitled, ‘Topical pharmaceutical composition comprising a cholinergic agent or a calcium channel blocker" is still pending.
Ventrus chairman and CEO Russell Ellison said this is a significant milestone for their company, since this provides patent protection in the US for the method of treatment, recited in the allowed claims, for the topical application of VEN 307 (2% diltiazem cream) for the treatment of anal fissures.